Last year was disruptive and difficult for everyone. Unfortunately, the challenegs and risks of COVID-19 had an outsized impact on much of the cancer community.

However, thanks in large part to PMC funding, Dana-Farber is one of the only cancer centers that was not forced to suspend clinical trials during the pandemic, ensuring the advancement of critical oncology research. PMC funding also helped Dana-Farber efficiently transition to telemedicine and invest heavily in patient and visitor safety protocols as COVID-19 continued. Many other research and treatment organizations were not as fortunate, making the continued work Dana-Farber even more important.

This year I am excited to get back on the bike for an (almost) normal PMC and continue the mission of raising funds for cancer research and treatment at Dana-Farber Cancer Institute.